Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2008-10-16
pubmed:abstractText
Treatment of ostial coronary lesions represents a challenge for interventional cardiologists. The efficacy of drug-eluting stents (DES) has been demonstrated as improving the outcomes of patients in a few studies. It is not known, however, which DES, sirolimus-eluting stent (SES) versus paclitaxel-eluting stent (PES), is superior for the treatment of ostial lesions.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0954-6928
pubmed:author
pubmed:issnType
Print
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
507-11
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:18923247-Aged, pubmed-meshheading:18923247-Angioplasty, Balloon, Coronary, pubmed-meshheading:18923247-Cardiovascular Agents, pubmed-meshheading:18923247-Cardiovascular Diseases, pubmed-meshheading:18923247-Coronary Angiography, pubmed-meshheading:18923247-Coronary Restenosis, pubmed-meshheading:18923247-Coronary Stenosis, pubmed-meshheading:18923247-Drug-Eluting Stents, pubmed-meshheading:18923247-Female, pubmed-meshheading:18923247-Humans, pubmed-meshheading:18923247-Male, pubmed-meshheading:18923247-Middle Aged, pubmed-meshheading:18923247-Odds Ratio, pubmed-meshheading:18923247-Paclitaxel, pubmed-meshheading:18923247-Retrospective Studies, pubmed-meshheading:18923247-Risk Assessment, pubmed-meshheading:18923247-Sirolimus, pubmed-meshheading:18923247-Time Factors, pubmed-meshheading:18923247-Treatment Outcome
pubmed:year
2008
pubmed:articleTitle
Drug-eluting stents for the treatment of ostial coronary lesions: comparison of sirolimus-eluting stent with paclitaxel-eluting stent.
pubmed:affiliation
Department of Cardiology, Fu Wai Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, PR China.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't